These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31251094)

  • 21. Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma.
    Albers FC; Bratton DJ; Gunsoy NB; Cockle SM; Alfonso-Cristancho R; Braunstahl GJ
    Clin Respir J; 2022 Mar; 16(3):252-258. PubMed ID: 35081275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
    Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
    J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
    Ortega H; Menzies-Gow A; Llanos JP; Forshag M; Albers F; Gunsoy N; Bradford ES; Yancey SW; Kraft M
    Adv Ther; 2018 Jul; 35(7):1059-1068. PubMed ID: 29949045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
    Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
    Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia.
    Condreay LD; Gao C; Bradford E; Yancey SW; Ghosh S
    Respir Med; 2019 Aug; 155():26-28. PubMed ID: 31295674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
    Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
    Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
    J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
    van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
    J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
    Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma.
    Ortega H; Yancey SW; Keene ON; Gunsoy NB; Albers FC; Howarth PH
    J Allergy Clin Immunol Pract; 2018; 6(3):980-986.e1. PubMed ID: 29398640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study.
    Müllerová H; Cockle SM; Gunsoy NB; Nelsen LM; Albers FC
    J Asthma; 2021 Apr; 58(4):459-470. PubMed ID: 31874051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of depressive symptoms with health status and markers of uncontrolled severe asthma.
    Khurana S; Lyness JM; Mallett S; Nelsen LM; Prazma CM; Albers FC; Forshag M; Llanos JP; Yancey SW; Ortega HG
    Allergy Asthma Proc; 2019 Jul; 40(4):230-239. PubMed ID: 31262378
    [No Abstract]   [Full Text] [Related]  

  • 37. Mepolizumab and exacerbations of refractory eosinophilic asthma.
    Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
    N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
    Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
    Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
    Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH; Wenzel SE; Thompson PJ; Prazma CM; Keene ON; Yancey SW; Ortega HG; Pavord ID;
    N Engl J Med; 2014 Sep; 371(13):1189-97. PubMed ID: 25199060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.